While Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) are making great progress in cancer treatments, the importance of early detection in combating this disease cannot be overstated. Today, a molecular genetics diagnostic company specializing in the early detection of cancer, Mainz Biomed NV (NASDAQ: MYNZ) revealed it made an important step on its mission to provide access to one such diagnostic test to people across the globe and by doing so, providing them with a lifechanging head start